These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 7859047)
1. Particle size: the key to the atherogenic lipoprotein? Rajman I; Maxwell S; Cramb R; Kendall M QJM; 1994 Dec; 87(12):709-20. PubMed ID: 7859047 [TBL] [Abstract][Full Text] [Related]
2. Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. Sattar N; Greer IA; Louden J; Lindsay G; McConnell M; Shepherd J; Packard CJ J Clin Endocrinol Metab; 1997 Aug; 82(8):2483-91. PubMed ID: 9253322 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein atherogenicity: an overview of current mechanisms. Griffin BA Proc Nutr Soc; 1999 Feb; 58(1):163-9. PubMed ID: 10343354 [TBL] [Abstract][Full Text] [Related]
4. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. Sartipy P; Camejo G; Svensson L; Hurt-Camejo E J Biol Chem; 1999 Sep; 274(36):25913-20. PubMed ID: 10464335 [TBL] [Abstract][Full Text] [Related]
5. LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow. Packard CJ Curr Med Res Opin; 1996; 13(7):379-90. PubMed ID: 8862937 [TBL] [Abstract][Full Text] [Related]
6. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size. Tani S; Matsumoto M; Nagao K; Hirayama A J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623 [TBL] [Abstract][Full Text] [Related]
7. [Serum lipoprotein and atherogenicity--relationship with particle size and composition of low density lipoproteins, and their modifications by oxidation and glycation]. Takeuchi N; Saheki S Rinsho Byori; 1995 Aug; 43(8):753-62. PubMed ID: 7474432 [TBL] [Abstract][Full Text] [Related]
8. Associations of low density lipoprotein particle composition with atherogenicity. Lada AT; Rudel LL Curr Opin Lipidol; 2004 Feb; 15(1):19-24. PubMed ID: 15166804 [TBL] [Abstract][Full Text] [Related]
9. Low density lipoprotein subfractions and [Ca2+]i in vascular smooth muscle cells. Weisser B; Locher R; de Graaf J; Vetter W Circ Res; 1993 Jul; 73(1):118-24. PubMed ID: 8508523 [TBL] [Abstract][Full Text] [Related]
10. Low density lipoprotein interaction with artery derived proteoglycan: the influence of LDL particle size and the relationship to atherosclerosis susceptibility. Wagner WD; Edwards IJ; St Clair RW; Barakat H Atherosclerosis; 1989 Jan; 75(1):49-59. PubMed ID: 2930613 [TBL] [Abstract][Full Text] [Related]
11. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Chapman MJ; Guérin M; Bruckert E Eur Heart J; 1998 Feb; 19 Suppl A():A24-30. PubMed ID: 9519339 [TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318 [TBL] [Abstract][Full Text] [Related]
14. Increased atherogenicity of low-density lipoprotein in heavy proteinuria. Deighan CJ; Caslake MJ; McConnell M; Boulton-Jones JM; Packard CJ Nephrol Dial Transplant; 1998 May; 13(5):1183-8. PubMed ID: 9623551 [TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262 [TBL] [Abstract][Full Text] [Related]